세계의 항비만제 시장 : 치료 유형, 약제 유형, 작용기전, 투여 경로, 유통 채널 및 지역별(-2035년)

Global Anti-Obesity Drugs Market Research Report by Treatment Type [Appetite Suppressants (Serotonin Norepinephrine Reuptake Inhibitors, Selective Serotonin 2C Receptor Agonists, Norepinephrine Dopamine Reuptake Inhibitors), Lipase Inhibitors, GLP-1 Receptor Agonists, Combination Drugs, Others], by Drug Type (Prescription Drugs, Over the Counter Drugs), by Mechanism of Action (Centrally Acting Anti-Obesity Drugs, Peripherally Acting Anti-Obesity Drugs), by Route of Administration (Oral, Subcutaneous), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and by Region (North America, Europe, Asia Pacific, South America, Middle East and Africa) Forecast till 2035

Industry Overview

The global anti-obesity drugs market, valued at USD 27.1623 billion in 2024, is projected to reach USD 326.8969 billion by 2035, growing at a CAGR of 25.82% from 2025 to 2035. Anti-obesity drugs refer to pharmaceutical treatments aimed at helping people achieve and maintain a healthier body weight. They work through various mechanisms, including appetite suppression, metabolism regulation, or nutrient absorption reduction. Such medications are usually recommended when lifestyle interventions alone are insufficient to manage obesity-related health concerns.

The global anti-obesity drugs market is experiencing extensive expansion, which is primarily attributed to the rising obese cases and the active governmental participation. Lifestyle changes, especially the way food is consumed and the trend of less physical activity, have prompted a demand for medical solutions. All over the globe, governments are implementing tactics such as public awareness programs, dietary guidelines, changing food habits, and subsidies for weight reduction activities.

The WHO's Global Action Plan on Physical Activity and Acceleration Plan to Stop Obesity are resulting in the adoption of more stringent prevention and treatment outlines by member states. Drug companies are innovating with new drug developments. For example, the efficacy of Wegovy and Mounjaro has been very promising in clinical trials, showing that the drugs can be a real alternative to bariatric surgery. The U.S. FDA's recent clearances and quicker regulatory pathways are making the distribution easier, particularly in developing countries.

Safety issues have always been the main obstacles for users, such as cardiovascular risk, gastric troubles, and psychiatric side effects. There are times when drug-caused severe complications have made manufacturers stop production and withdraw the products. Hence, gaining the confidence of patients should be a healthcare priority currently. In any case, considering the upward trend for healthcare costs related to obesity, the bright scenario in which policy support, technological innovation, and health awareness combined to provoke the market's sustained strong growth in the next years.

Industry Segmentations

In terms of the drug type, the global market is classified into prescription drugs and over-the-counter drugs.

Oral and subcutaneous are part of the route of administration of the global anti-obesity drugs market.

Appetite suppressants, lipase inhibitors, GLP-1 receptor agonists, combination drugs, and others are the treatment type category of the global market. Appetite suppressants are further segmented into Serotonin Norepinephrine reuptake inhibitors, selective serotonin 2C receptor agonists, and Norepinephrine Dopamine Reuptake inhibitors.

Based on the mechanism in action, the global market is divided into centrally acting anti-obesity drugs and peripherally acting anti-obesity drugs.

The global anti-obesity drugs market is segmented by the distribution channel, comprising hospital, retail, and online pharmacies.

Regional Analysis

North America's supremacy in the anti-obesity drugs market is the main factor that keeps the region at the top of the list of global leaders in innovative pharmaceutical solutions. Companies based in the U.S. are at the forefront of introducing new drug classes such as GLP-1 receptor agonists and dual-action molecules. Moreover, this area is also advantaged by a good practice of early acceptance of new medical technologies. Favorable reimbursement strategies are the fuel for swift market infiltration after a drug has been approved.

Europe's R&D spending on obesity therapies has grown, primarily in countries such as the UK, Denmark, and Germany. Novo Nordisk's facilities in Denmark have paved the way for the area to be a center for revolutionary treatments. The cross-border healthcare research projects are allowing quicker access to the trial data, thus, the development stages are shorter. The public's reliance on prescription drugs is high, which is helpful in the dissemination once safety and effectiveness are verified. Besides, the region is witnessing a trend of personalized obesity treatment plans incorporating pharmacotherapy with diet and exercise.

The obesity problem in the Asia-Pacific region is a significant factor pushing domestic as well as global companies to pour a lot of money into clinical research focusing on the Asian genetic and lifestyle profiles. Japan's and South Korea's pharmaceutical companies are creating Japanese and South Korean versions of the same drug to reduce the side effects for local populations. Governments are supporting clinical trials by offering tax benefits and lessening the regulations. Some are interested in oral obesity drugs rather than injection forms, so that patients can be comfortable. So, the multinationals are taking the region as a place to test inexpensive obesity treatments.

The South American region is gradually becoming the hub of R&D collaborations. One of the reasons for this trend is the fact that Brazil is gaining ground as the best place to conduct obesity-related clinical trials due to the diversity of the patient pool. Moreover, local biotech startups are forming alliances with global pharmaceutical companies to co-create cost-effective therapies. Nations are trying to decrease the level of their reliance on imports by promoting the local drug production sector. The collaborations between the public and private sectors are taking place to facilitate the regulatory approvals for the revolutionary treatments. The research on weight loss drugs in this area is mainly done on patients suffering from metabolic syndrome, which indicates the concern of local health officials.

In the Middle East & Africa, research is often aimed at understanding obesity in relation to cultural and dietary habits unique to the region. Universities in Gulf countries are collaborating with pharmaceutical companies to study obesity genetics among Arab populations. Investments in local manufacturing facilities are increasing to reduce import costs. Partnerships with global leaders ensure technology transfer and skill development for regional scientists. Drug innovation here often includes patient education programs to boost long-term adherence.

Key Players

Major competitors in the global anti-obesity drugs market are Novo Nordisk A/S, Rhythm Pharmaceuticals, Inc., KVK Tech, Inc., Currax Pharmaceuticals LLC, VIVUS LLC, Eli Lilly and Company, AstraZeneca, GSK Plc, Gelesis, and CHEPLAPHARM Arzneimittel GmbH.

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

• 2.1 DEFINITION
• 2.2 SCOPE OF THE STUDY
• 2.3 RESEARCH OBJECTIVE
• 2.4 MARKET STRUCTURE

3 RESEARCH METHODOLOGY

• 3.1 OVERVIEW
• 3.2 DATA FLOW
  • 3.2.1 DATA MINING PROCESS
• 3.3 PURCHASED DATABASE:
• 3.4 SECONDARY SOURCES:
  • 3.4.1 SECONDARY RESEARCH DATA FLOW:
• 3.5 PRIMARY RESEARCH:
  • 3.5.1 PRIMARY RESEARCH DATA FLOW:
  • 3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED
  • 3.5.3 PRIMARY RESEARCH: REGIONAL COVERAGE
• 3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
  • 3.6.1 REVENUE ANALYSIS APPROACH
• 3.7 DATA FORECASTING
  • 3.7.1 DATA FORECASTING TYPE
• 3.8 DATA MODELING
  • 3.8.1 MICROECONOMIC FACTOR ANALYSIS:
  • 3.8.2 DATA MODELING:
• 3.9 TEAMS AND ANALYST CONTRIBUTION

4 MARKET DYNAMICS

• 4.1 INTRODUCTION
• 4.2 DRIVERS
  • 4.2.1 RISING PREVALENCE OF OBESITY
  • 4.2.2 INCREASING GOVERNMENT INITIATIVES AND SUPPORT
• 4.3 RESTRAINTS
  • 4.3.1 SIDE EFFECTS AND SAFETY CONCERNS
• 4.4 OPPORTUNITY
  • 4.4.1 FOCUS ON NON-SURGICAL OBESITY TREATMENTS

5 MARKET FACTOR ANALYSIS

• 5.1 PORTER'S FIVE FORCES MODEL
  • 5.1.1 THREAT OF NEW ENTRANTS
  • 5.1.2 BARGAINING POWER OF SUPPLIERS
  • 5.1.3 THREAT OF SUBSTITUTES
  • 5.1.4 BARGAINING POWER OF BUYERS
  • 5.1.5 INTENSITY OF RIVALRY
• 5.2 IMPACT OF COVID-19 ON GLOBAL ANTI-OBESITY DRUGS MARKET
• 5.3 MARKET TRENDS
• 5.4 REGULATORY LANDSCAPE
  • 5.4.1 NORTH AMERICA
  • 5.4.2 EUROPE
  • 5.4.3 ASIA-PACIFIC
  • 5.4.4 LATIN AMERICA
  • 5.4.5 MIDDLE EAST AND AFRICA
• 5.5 UNMET NEEDS
• 5.6 EPIDEMIOLOGY ASSESSMENT
• 5.7 BRAND AND PIPELINE ANALYSIS
• 5.8 PRICING ANALYSIS

6 GLOBAL ANTI-OBESITY DRUGS MARKET, BY TREATMENT TYPE

• 6.1 OVERVIEW
• 6.1 APPETITE SUPPRESSANTS
  • 6.1.1 SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS
  • 6.1.2 SELECTIVE SEROTONIN 2C RECEPTOR AGONISTS
  • 6.1.3 NOREPINEPHRINE-DOPAMINE REUPTAKE INHIBITORS (NDRIS)
• 6.2 LIPASE INHIBITORS
• 6.3 GLP-1 RECEPTOR AGONISTS
• 6.4 COMBINATION DRUGS
• 6.5 OTHERS

7 GLOBAL ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE

• 7.1 OVERVIEW
• 7.2 PRESCRIPTION DRUGS
• 7.3 OVER THE COUNTER DRUGS

8 GLOBAL ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION

• 8.1 OVERVIEW
• 8.2 CENTRALLY ACTING ANTI-OBESITY DRUGS
• 8.3 PERIPHERALLY ACTING ANTI-OBESITY DRUGS

9 GLOBAL ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION

• 9.1 OVERVIEW
• 9.2 ORAL
• 9.3 SUBCUTANEOUS

10 GLOBAL ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL

• 10.1 OVERVIEW
• 10.2 HOSPITAL PHARMACIES
• 10.3 RETAIL PHARMACIES
• 10.4 ONLINE PHARMACIES

11 GLOBAL ANTI-OBESITY DRUGS MARKET, BY REGION

• 11.1 OVERVIEW
• 11.2 NORTH AMERICA
  • 11.2.1 US
  • 11.2.2 CANADA
• 11.3 EUROPE
  • 11.3.1 GERMANY
  • 11.3.2 FRANCE
  • 11.3.3 UK
  • 11.3.4 SPAIN
  • 11.3.5 ITALY
  • 11.3.6 RUSSIA
  • 11.3.7 REST OF EUROPE
• 11.4 ASIA PACIFIC
  • 11.4.1 CHINA
  • 11.4.2 INDIA
  • 11.4.3 JAPAN
  • 11.4.4 SOUTH KOREA
  • 11.4.5 MALAYSIA
  • 11.4.6 THAILAND
  • 11.4.7 INDONESIA
  • 11.4.8 REST OF ASIA PACIFIC
• 11.5 SOUTH AMERICA
  • 11.5.1 BRAZIL
  • 11.5.2 MEXICO
  • 11.5.3 ARGENTINA
  • 11.5.4 REST OF SOUTH AMERICA
• 11.6 MIDDLE EAST AND AFRICA
  • 11.6.1 GCC COUNTRIES
  • 11.6.2 SOUTH AFRICA
  • 11.6.3 REST OF MEA

12 COMPETITIVE LANDSCAPE

• 12.1 INTRODUCTION
• 12.2 MARKET SHARE ANALYSIS, 2024
• 12.3 COMPETITOR DASHBOARD
• 12.4 PUBLIC PLAYERS STOCK SUMMARY
• 12.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANCIAL
• 12.1 KEY DEVELOPMENTS & GROWTH STRATEGIES
  • 12.1.1 PRODUCT APPROVAL
  • 12.1.2 MARKETING APPROVAL
  • 12.1.3 PRODUCT EXPANSION
  • 12.1.4 FACILITY LAUNCH
  • 12.1.5 AQUISITION
  • 12.1.6 AGREEMENT

13 COMPANY PROFILES

• 13.1 ELI LILLY AND COMPANY
  • 13.1.1 COMPANY OVERVIEW
  • 13.1.2 FINANCIAL OVERVIEW
  • 13.1.3 PRODUCTS OFFERED
  • 13.1.4 KEY DEVELOPMENTS
  • 13.1.5 SWOT ANALYSIS
  • 13.1.6 KEY STRATEGIES
• 13.2 ASTRAZENECA
  • 13.2.1 COMPANY OVERVIEW
  • 13.2.2 FINANCIAL OVERVIEW
  • 13.2.3 PRODUCTS OFFERED
  • 13.2.4 KEY DEVELOPMENTS
  • 13.2.5 SWOT ANALYSIS
  • 13.2.6 KEY STRATEGIES
• 13.3 GSK PLC
  • 13.3.1 COMPANY OVERVIEW
  • 13.3.2 FINANCIAL OVERVIEW
  • 13.3.3 PRODUCT OFFERED
  • 13.3.4 KEY DEVELOPMENTS
  • 13.3.5 SWOT ANALYSIS
  • 13.3.6 KEY STRATEGIES
• 13.4 GELESIS
  • 13.4.1 COMPANY OVERVIEW
  • 13.4.2 FINANCIAL OVERVIEW
  • 13.4.3 PRODUCTS OFFERED
  • 13.4.4 KEY DEVELOPMENTS
  • 13.4.5 KEY STRATEGIES
• 13.5 CHEPLAPHARM ARZNEIMITTEL GMBH
  • 13.5.1 COMPANY OVERVIEW
  • 13.5.2 FINANCIAL OVERVIEW
  • 13.5.3 PRODUCT OFFERED
  • 13.5.4 KEY DEVELOPMENTS
  • 13.5.5 KEY STRATEGIES
• 13.6 NOVO NORDISK A/S
  • 13.6.1 COMPANY OVERVIEW
  • 13.6.2 FINANCIAL OVERVIEW
  • 13.6.3 PRODUCTS OFFERED
  • 13.6.4 KEY DEVELOPMENTS
  • 13.6.5 SWOT ANALYSIS
  • 13.6.6 KEY STRATEGIES
• 13.7 RHYTHM PHARMACEUTICALS, INC.
  • 13.7.1 COMPANY OVERVIEW
  • 13.7.2 FINANCIAL OVERVIEW
  • 13.7.3 PRODUCTS OFFERED
  • 13.7.4 KEY DEVELOPMENTS
  • 13.7.5 SWOT ANALYSIS
  • 13.7.6 KEY STRATEGIES
• 13.8 KVK TECH, INC.
  • 13.8.1 COMPANY OVERVIEW
  • 13.8.2 FINANCIAL OVERVIEW
  • 13.8.3 PRODUCTS OFFERED
  • 13.8.4 KEY DEVELOPMENTS
  • 13.8.5 KEY STRATEGIES
• 13.9 CURRAX PHARMACEUTICALS LLC
  • 13.9.1 COMPANY OVERVIEW
  • 13.9.2 FINANCIAL OVERVIEW
  • 13.9.3 PRODUCTS OFFERED
  • 13.9.4 KEY DEVELOPMENTS
  • 13.9.5 KEY STRATEGIES
• 13.10 VIVUS LLC
  • 13.10.1 COMPANY OVERVIEW
  • 13.10.2 FINANCIAL OVERVIEW
  • 13.10.3 PRODUCTS OFFERED
  • 13.10.4 KEY DEVELOPMENTS
  • 13.10.5 KEY STRATEGIES

14 DATA CITATIONS